

Clinical trials of probucol

TrialResults-center www.trialresultscenter.org

1 cardiovascular prevention

Trial	Treatments	Patients	Trials design and methods
probucol vs control			
FATS Fukosawa (probucol) , 2002 n=82/81 follow-up: 2 years	probucol 500 mg/day versus diet alone	asymptomatic patients with hypercholesterolemia	Parallel groups open Japan
Probucol vs placebo			
PQRST , 1994 n=152/151 follow-up: 3 ans	Probucol 1 g / j pendant 3 ans versus placebo, de mme aspect(2 tablettes par jour)pendant 3 ans	Stade II: 70%	Parallel groups Double aveugle
McCaughan , 1981 n=88/30 follow-up: 1 year	probucol versus placebo	hypercholesterolemic men	Parallel groups double-blind
PQRST , 1994 n=NA follow-up: 3 y	probucol 0.5 g twice daily versus placebo	hypercholesterolemic patients with visible atherosclerosis	Parallel groups double blind
Tardif , 1997 n=160/157 follow-up: 0.5 years	probucol 500 mg versus placebo	patients undergoing PTCA	Parallel groups open

More details and results :

- cholesterol lowering intervention for cardiovascular prevention in patients with LDL elevation and without CHD at <http://www.trialresultscenter.org/go-Q5>
- cholesterol lowering intervention for cardiovascular prevention in patients with prior MI or with CHD at <http://www.trialresultscenter.org/go-Q12>
- cholesterol lowering intervention for cardiovascular prevention in all chronical situations at <http://www.trialresultscenter.org/go-Q154>

References

FATS Fukosawa (probucol), 2002:

Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002 Feb 20;39:610-6 [[11849859](#)]

PQRST, 1994:

Probucol Quantitative Regression Swedish Trial: new angiographic technique to measure atheroma volume of the femoral artery. Erikson U, Nilsson S, Stenport G Am J Cardiol 1988 Jul 25;62:44B-47B [[3293416](#)]

Holme I, Malmaeus I, Olsson AG, Nilsson S, Walladius G. Repeated measurements over time: statistical analysis of the angiographic outcomes in the Probucol Quantitative Regression Swedish Trial (PQRST). Clinical Trials and Meta-Analysis 1993;28:95-108

Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report. Walldius G, Carlson LA, Erikson U, Olsson AG, Johansson J, Molgaard J, Nilsson S, Stenport G, Kaijser L, Lassvik C, et al Am J Cardiol 1988 Jul 25;62:37B-43B [[3293415](#)]

The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, Kaijser L, Lassvik C, Molgaard J, Nilsson S, et al Am J Cardiol 1994 Nov 1;74:875-83 [[7977117](#)]

The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Walldius G, Regnstrom J, Nilsson J, Johansson J, Schafer-Elinder L, Moelgaard J, Hadell K, Olsson AG, Carlson LA Am J Cardiol 1993 Feb 25;71:15B-19B [[8434556](#)]

McCaughan, 1981:

McCaughan D The long-term effects of probucol on serum lipid levels. Arch Intern Med 1981;141:1428-32 [[7025778](#)]

PQRST, 1994:

Walldius G, Erikson U, Olsson AG, Bergstrand L, Hdell K, Johansson J, Kaijser L, Lassvik C, Mlgaard J, Nilsson S The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83 [[7977117](#)]

Walldius G, Regnstrm J, Nilsson J, Johansson J, Schfer-Elinder L, Moelgaard J, Hdell K, Olsson AG, Carlson LA The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1993;71:15B-19B [[8434556](#)]

Walldius G, Carlson LA, Erikson U, Olsson AG, Johansson J, Mlgaard J, Nilsson S, Stenport G, Kaijser L, Lassvik C Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report. Am J Cardiol 1988;62:37B-43B [[3293415](#)]

Walldius G, Erikson U, Olsson AG, Bergstrand L, Hdell K, Johansson J, Kaijser L, Lassvik C, Mlgaard J, Nilsson S The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83 [[7977117](#)]

Tardif, 1997:

Tardif JC, Ct G, Lesprance J, Bourassa M, Lambert J, Doucet S, Bilodeau L, Nattel S, de Guise P Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-72 [[9241125](#)]

2 coronary artery disease

Trial	Treatments	Patients	Trials design and methods
dual sirolimus, probucol eluting stent vs sirolimus eluting stent			
ISAR TEST 2 (vs SES) , 2009 [NCT00332397] n=333/335 follow-up: 12 months	dual DES (polymer-free stent consisting of probucol and rapamycin) versus SES	patients with De novo lesions in native coronary arteries	Parallel groups open Germany
dual sirolimus, probucol eluting stent vs zotarolimus eluting stent			
ISAR TEST 2 (vs ZES) , 2009 [NCT00332397] n=333/339 follow-up: 12 months	dual DES (polymer-free stent consisting of probucol and rapamycin) versus permanent polymer zotarolimus-eluting stent (Endeavor)	patients with De novo lesions in native coronary arteries	Parallel groups open Germany
ISAR TEST 5 [NCT00598533] n=2002/1000 follow-up: 1 year	polymer-free, rapamycin/probucol-eluting Dual-DES stent versus zotarolimus-eluting stent with a modified permanent polymer on a cobalt-chromium alloy platform	"all-comers" population	Parallel groups

3

More details and results :

- myocardial revascularization for coronary artery disease in all type of patient at <http://www.trialresultscenter.org/go-Q26>
- Drug eluting stent for coronary artery disease in all type of patients at <http://www.trialresultscenter.org/go-Q206>

References

ISAR TEST 2 (vs SES), 2009:

Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schmig A, Kastrati A A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009;: [19240066]

Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schmig A, Kastrati A A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009;30:923-31 [19240066]

Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Piniack S, Massberg S, Seyfarth M, Laugwitz KL, Birkmeier KA, Schmig A, Mehilli J 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor, drug-eluting stents. J Am Coll Cardiol 2010 Jun 8;55:2536-43 [20417052] 10.1016/j.jacc.2010.03.020

ISAR TEST 2 (vs ZES), 2009:

Byrne RA ISAR-TEST 2: A prospective randomized trial comparing polymer-free rapamycin and probucol-eluting stents, polymer-based sirolimus-eluting stents, and zotarolimus-eluting stents in patients with coronary artery disease. TCT, October 16, 2008.

Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schmig A, Kastrati A A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. Eur Heart J 2009 Feb 24; [19240066]

Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Piniack S, Massberg S, Seyfarth M, Laugwitz KL, Birkmeier KA, Schmig A, Mehilli J 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor, drug-eluting stents. J Am Coll Cardiol 2010 Jun 8;55:2536-43 [20417052] 10.1016/j.jacc.2010.03.020

ISAR TEST 5, :

3 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
probucol vs placebo			
PQRST, 1994 n=152/151 follow-up: 3 ans	Probucol 1 g / j pendant 3 ans versus placebo, de mme aspect(2 tablettes par jour)pendant 3 ans	Stade II: 70%	Parallel groups Double aveugle

More details and results :

- cholesterol lowering intervention for peripheral vascular diseases in all type of patients at <http://www.trialresultscenter.org/go-Q52>

References

PQRST, 1994:

Probucol Quantitative Regression Swedish Trial: new angiographic technique to measure atheroma volume of the femoral artery. Erikson U, Nilsson S, Stenport G Am J Cardiol 1988 Jul 25;62:44B-47B [3293416]

Holme I, Malmaeus I, Olsson AG, Nilsson S, Walladius G. Repeated measurements over time: statistical analysis of the angiographic outcomes in the Probucol Quantitative Regression Swedish Trial (PQRST). Clinical Trials and Meta-Analysis 1993;28:95-108

Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report. Walldius G, Carlson LA, Erikson U, Olsson AG, Johansson J, Molgaard J, Nilsson S, Stenport G, Kaijser L, Lassvik C, et al Am J Cardiol 1988 Jul 25;62:37B-43B [3293415]

The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, Kaijser L, Lassvik C, Molgaard J, Nilsson S, et al Am J Cardiol 1994 Nov 1;74:875-83 [7977117]

The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST). Walldius G, Regnstrom J, Nilsson J, Johansson J, Schafer-Elinder L, Moelgaard J, Hadell K, Olsson AG, Carlson LA Am J Cardiol 1993 Feb 25;71:15B-19B [8434556]

Entry terms: Probucol, DH-581, DH 581, DH581, Lorelco, Lurselle, Superlipid, Biphenabid, Panavir,